Mode
Text Size
Log in / Sign up

Cardio Heart Connect intervention aims to improve daily steps for patients post-TAVR procedureNew trial plans to test fitness apps for heart patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that this is a study protocol; no results are currently available to inform clinical practice.

The proposed randomized trial will enroll 200 patients at the University of Colorado Hospital Heart and Vascular Center who have been placed on a cardiac rehab waitlist following a TAVR procedure. The study aims to evaluate the impact of the Cardio Heart Connect intervention, which utilizes commercially available fitness programming, compared to an attention control designed to account for technology access.

The primary outcome is measured as daily steps via smartwatch accelerometer. Secondary outcomes include functional capacity (Duke Activity Status Index; VO2max), quality of life (Kansas City Cardiomyopathy Questionnaire), and cardiovascular health status (Life Essential 8). Follow-up periods are planned for 8 weeks and 12 months.

Safety data, including adverse events and tolerability, are not reported. A primary limitation is that this is a protocol for a planned trial; therefore, no results have been collected or analyzed yet. The study aims to determine if mHealth programming provides accessible physical activity opportunities for patients recovering from TAVR.

How this fits prior evidence

How this fits prior evidence: This protocol addresses a gap in accessible rehabilitation options for aortic valve disease patients post-TAVR. It does not relate to the previously reported finding that argatroban switch stabilized clinical status in a patient with mechanical aortic valve and LVAD after HIT.

Recovering from a TAVR procedure, which is a way to repair an aortic valve, can be a long road. Patients often face a waitlist to start formal cardiac rehabilitation. During this time, staying active is vital but can be hard to manage without constant guidance.

Researchers at the University of Colorado Hospital Heart and Vascular Center are planning a study to see if technology can bridge that gap. They will test the Cardio Heart Connect program, which uses commercially available fitness tools. The goal is to see if these digital programs help patients hit their daily step goals while they wait for official rehab.

The trial plans to follow 200 patients over 8 weeks and up to 12 months. While the study is still in the planning phase and has not started yet, it aims to find better ways to keep heart patients moving. Because no results are available yet, we cannot say if the app will be more effective than standard care.

What this means for you:
A planned trial will test if mobile fitness apps help aortic valve patients stay active while on rehab waitlists.

Common questions

Who is this program for?

This study specifically targets patients who have undergone a TAVR procedure and are currently on a waitlist for cardiac rehabilitation. These individuals often need ways to stay active during their recovery period.

What exactly will the trial measure?

The primary goal is to track daily steps using smartwatch accelerometers. The study also plans to look at functional capacity, quality of life, and overall cardiovascular health status over a period of 8 weeks and 12 months.

Are there results available yet?

No, because this is a protocol for a planned trial, the study has not been conducted yet. No results or safety data are currently available to share.

Study Details

Study typeRct
Sample sizen = 200
EvidenceLevel 2
PublishedJun 2026
View Original Abstract ↓
Background: Despite ample evidence of the benefits of cardiac rehabilitation (CR), few transcatheter aortic valve replacement (TAVR) patients participate. Commercially available mobile health offers an opportunity to deliver activity-promotion content to populations that are challenged to participate in CR. This study aims to test the efficacy of clinically controlled, commercially available fitness programming for improving physical activity and cardiovascular health outcomes designed to be initiated while patients are on waitlists for traditional CR. Methods: The Cardio Heart Connect study is a hybrid type I effectiveness-implementation trial aiming to enroll N=200 patients who have been placed on a cardiac rehab waitlist following a TAVR procedure from the University of Colorado Hospital Heart and Vascular Center. Participants will be randomized 1:1 to the Cardio Heart Connect intervention with commercially available fitness or attention control, designed to control for technology access. At baseline, post-intervention (8 weeks), and follow-up (12 months), we will assess the primary outcome of participants? daily steps as measured by smartwatch accelerometer and secondary outcomes of interest including functional capacity (Duke Activity Status Index; VO2max), quality of life (Kansas City Cardiomyopathy Questionnaire), and cardiovascular health status (Life Essential 8). In addition, we will use mixed methodologies to evaluate the implementation of intervention using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) Framework. Conclusions: Commercially available fitness programs have the potential to provide more accessible opportunities for patients recovering from TAVR to engage in physical activity and may be preferred due to their customizability, convenience, and ease of scheduling. Overall, this study will provide insight into the use of commercial mHealth to promote activity following TAVR.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.